These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 24505856

  • 1. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C.
    Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856
    [Abstract] [Full Text] [Related]

  • 2. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT.
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [Abstract] [Full Text] [Related]

  • 3. Teva v. Eisai: what's the real "controversy"?
    Wang GL.
    Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
    [Abstract] [Full Text] [Related]

  • 4. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA.
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [Abstract] [Full Text] [Related]

  • 5. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL.
    Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
    [Abstract] [Full Text] [Related]

  • 6. A new history and discussion of 180-day exclusivity.
    Korn DE, Lietzan E, Scott SW.
    Food Drug Law J; 2009 Feb; 64(2):335-90. PubMed ID: 19999288
    [Abstract] [Full Text] [Related]

  • 7. A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act.
    Lietzan EK.
    Food Drug Law J; 2004 Feb; 59(2):287-323. PubMed ID: 15298013
    [Abstract] [Full Text] [Related]

  • 8. Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.
    Grabowski HG, Kyle M, Mortimer R, Long G, Kirson N.
    Health Aff (Millwood); 2011 Nov; 30(11):2157-66. PubMed ID: 22068409
    [Abstract] [Full Text] [Related]

  • 9. The new follow-on-biologics law: a section by section analysis of the patent litigation provisions in the Biologics Price Competition and Innovation Act of 2009.
    Dougherty MP.
    Food Drug Law J; 2010 Nov; 65(2):231-45, i. PubMed ID: 24475541
    [Abstract] [Full Text] [Related]

  • 10. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
    Rea TS.
    Food Drug Law J; 1999 Nov; 54(2):223-5. PubMed ID: 11759713
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H.
    Food Drug Law J; 2003 Nov; 58(1):51-80. PubMed ID: 12739584
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A shift on "pay for delay"--reopening doors for pharmaceutical competition?
    Hemphill Kraus EJ.
    N Engl J Med; 2012 Nov 01; 367(18):1681-3. PubMed ID: 23113478
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.